Cold laser treatment methods is a somewhat innovative technology when compared to the a great number of alternative therapies such as
acupuncture (that's been practiced since 8000-3500 B.C.), chiropractic (since
1895) as well as physical therapy. Just like the abacus evolved into the
computer, a variety of alternative medicine practices are expanding to also
include light therapy. More recent advancements in low-level lasers now make it
possible for the average medical professional or individual to own cold laser
equipment. Cold lasers are sometimes called Low Level Lasers (LLL) or soft
lasers.
Cold Laser treatment offers a non-intrusive option to acupuncture
and surgery. It additionally allows for a non-addicting treatment which usually
eliminates the complications associated with long-term medication treatment
programs. Cold lasers tend to be commonly utilized for treatment associated
with: Acute and chronic joint pain, Tendon strains, Muscle strain, Soft tissue
injuries, Tendonitis, Arthritis, Tennis elbow, Back soreness, Bursitis, Carpal
Tunnel Syndrome, in addition to Fibromyalgia.
In general, cold lasers
usually are implemented in 2 specific methods. One is in fact Targeting
acupuncture trigger points (analogous to acupuncture however minus the needles)
and the other is actually by using Wide coverage of deep tissue with laser
photons in order to spark changes within the tissue.
The cold laser
creates an impulse of light at a specific wave length (typically 905nm)
which will diminishes reflection in addition to scattering but maximized
absorption of the energy (in photons) at a desire depth.
Various
conditions such as joint pain involve a deep penetration (4-5 inches) that can
only be accomplished using a super-pulsed laser emitter. Many systems also contain
other lower wavelengths in addition to lower-power emitters for treating shallow
tissue (like the lymph system or even surface scars). In addition, red light diode with a wave length of 660 nm could be utilized to add energy to even shallower levels of tissues. It is
definitely the over-all judgement that wavelengths less than 660 nanometers are
usually very easily absorbed within the surface tissue and are not optimized
pertaining to deep tissue healing.
The purpose of laser therapies is to
provide light energy units via infrared laser radiation, referred to as photons,
to damaged cells. It is the preference of industry experts is that photons
absorbed by the cells by way of laser therapy stimulate the mitochondria to
boost production of ATP. This specific biochemical increase in cell energy can
be utilized to enhance live cells from a state connected with illness to a
stable, healthy state.
About 4000 reports have actually been performed in
recent years to actually validate the effectiveness regarding cold laser
therapies. The following actually are some of the particular advantages
connected with Cold Laser Therapies. The therapy is definitely simple to
implement, very safe, non-toxic, non-invasive, zero side effects or discomfort,
cost effective with regard to both the practitioner and patient, particularly
effective in treating ailments (more than 90% efficacy), superior alternative to
pain killers, reduces the need regarding surgery, and often will work
synergistically along with other modalities such as Chiro, Acupuncture, as well
as Rehabilitation.
At this time, lasers are employed substantially in the
medical industry intended for everything from cosmetic surgery, eye surgery and
also heart surgery. The particular ability to place merely the right amount of
energy straight into a vital spot of the human body is a fantastic advancement
throughout the medical field. Cold lasers are usually an essential addition to
these various other established medical laser treatments and the recent
development involving professional cold lasers suggests that cold laser
therapy will probably be a rapidly growing non-invasive medical treatment option.
For more information please call 1-866-843-5273 or visit www.theralase.com
Thursday, May 23, 2013
Thursday, May 16, 2013
Theralase Advanced Cancer Therapy Research Recognized at Major International Conference
Toronto, Ontario – May 16, 2013, Theralase Technologies Inc. (TSXV: TLT)
(“Theralase”) announced today that its researchers have discovered a
significant new mechanism of action for a new class of Photo Dynamic Compounds
(PDCs), that have been custom designed to destroy cancer cells when activated
by a proprietary light source.
The preclinical
study, conducted by Theralase scientists and their colleagues at University
Health Network’s Princess Margaret Cancer Centre, was presented on May 15, at
the Laser World of Photonics conference held in Munich, Germany.
In previous
preclinical studies, Theralase’s PDCs have been proven to be promising anti-cancer
agents in various cancer models. Their efficacy involved a number of critical
cellular processes, including DNA damage and programmed cell death. All PDCs
were thought to work primarily by oxygen-dependent mechanisms, ultimately
causing cell death in the presence of highly reactive oxygen. In this study;
however, scientists established that a new class of Theralase PDCs have an
additional “oxygen independent” mechanism of action, which would increase
efficacy in the destruction of more clinically aggressive tumours.
The
research lead by Dr. Lothar Lilge, Senior Scientist, Ontario Cancer Institute, Princess
Margaret Cancer Centre and Dr. Arkady Mandel, Chief Scientific Officer, Theralase
has shown that specific metal-based PDCs when tested for effectiveness of
cancer destruction in a low oxygen environment were proven to be highly
effective in the destruction of human brain cancer cells in-vitro, thus activating this newly discovered pathway. Additionally
using this pathway, Theralase scientists confirmed in a preclinical model a complete response rate and the
destruction of subcutaneous (under the skin) colon cancer tumours in mice,
which were treated with Theralase’s anti-cancer PDC technology. On follow-up, the
initial complete response was maintained in two-thirds of the animals for over
1 year without recurrence.
Roger
Dumoulin-White, President and CEO of Theralase Technologies Inc. stated,
“Recognition of our world class anti-cancer research at the Munich conference
is another testament to the cutting edge research our scientists are conducting
in this field. Our findings would strongly suggest that Theralase’s PDCs oxygen
independent potency would significantly enhance our ability to destroy cancer
cells. Tumours in a low oxygen environment have been extremely challenging because
this lack of oxygen renders solid tumours much more resistant to therapeutic
interventions. Many traditional therapeutic agents, conducted on
poorly oxygenated solid core tumours, including any currently FDA approved PDCs, are susceptible to a
“self-limiting” activity; whereby, below a critical threshold oxygenation level,
their efficacy is progressively reduced resulting in minimal to no cancer cell
destruction. This new class of Theralase PDCs are not susceptible to this “self-limiting”
activity and as a result maintain their efficacy even in extremely low oxygenated
cancerous tumours, such as breast and prostate cancer. As a result, Theralase is extremely
excited about the latest research and what it means in the field of cancer
destruction. Theralase is committed to the early commercialization of its patented
light activated Photo Dynamic Compounds in the areas of anti-cancer and
anti-bacterial applications to generate substantial revenues for the Company
and hence dramatically increase shareholder value.”
About Theralase Technologies Inc.
Theralase
Technologies Inc., founded in 1995, designs, develops, manufactures and markets
patented, superpulsed laser technology utilized in biostimulation and
biodestruction applications. Theralase technology is safe and effective in
treating pain, inflammation and for tissue regeneration of neural muscular
skeletal conditions Theralase is currently developing patented Photo Dynamic
Compounds (PDCs) that are able to target and destroy cancers, bacteria and
viruses when light activated by Theralase’s proprietary laser technology.
For
further information please visit www.theralase.com
, regulatory filings may be viewed by visiting www.sedar.com.
This press release
contains forward-looking statements, which reflect the Company's current
expectations regarding future events. The forward-looking statements involve
risks and uncertainties. Actual results could differ materially from those
projected herein. The Company disclaims any obligation to update these
forward-looking statements.
Neither TSX Venture
Exchange nor its Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchanges) accepts responsibility for the adequacy
or accuracy of this release.
For More Information, please contact:
Roger Dumoulin-White,
President & CEO
416-699-LASE (5273) ext. 225
Kristina Hachey
Chief Financial Officer
416-699-LASE (5273) ext. 224
Greg Bewsh
Director of Investor Relations
416-699-LASE (5273) ext. 258
Arkady
Mandel
Chief
Scientific Officer
416-699-LASE
(5273) ext. 260
Monday, May 6, 2013
Theralase Technologies Inc. Executive Summary – 2013
Company
Theralase Technologies Inc. (TSXV: TLT) designs, develops
and manufactures patented, superpulsed laser technology used in a wide range of
biostimulation and biodestruction clinical applications. The Theralase
technology platform targets several diverse healthcare sectors:
Theralase Technologies Inc. is focused on a two‐part
strategy:
1. Production, marketing and distribution of the Theralase
Superpulsed Laser for sale to health care practitioners that are dedicated to the
treatment of chronic pain, sports injuries and wounds. In 4Q2013, launch the
patented TLC‐2000 biofeedback laser system internationally to provide a quantum
leap in therapeutic laser technology.
2. Commercialization of patented cancer technology through preclinical
research, human clinical trials and regulatory approvals in the direct
destruction of cancer.
Science
In 1917, Albert Einstein first published the principle of Light Amplification by Stimulated
Emission of Radiation, or quite simply lasers. In June 1960, Theodoro H. Maiman
constructed, using a ruby crystal, the first operational laser. In 1965,
doctors Sinclair, Knoll and Mester pioneered the way for therapeutic lasers;
lasers that do not cut or destroy tissue, but lasers that heal and have a
therapeutic curative effect on tissue. Approximately 3,000 clinical studies
worldwide have attested to the beneficial and curative effects of therapeutic
lasers. In the last twenty years, therapeutic lasers have dramatically
increased in power and effectiveness and decreased in cost and size.
Therapeutic laser therapy is a universal way of treating and
healing tissue structures, such as: muscles, tendons, ligaments, joints,
connective tissues, bones and skin. There are thousands of tissue conditions
that therapeutic medical lasers can be applied to, such as: pain relief,
muscular‐skeletal conditions, nerve rehabilitation, wound healing, anti‐aging
and addiction therapy.
Biodestructive laser therapy uses proprietary laser
technology to activate the Photo Dynamic key of specifically designed Photodynamic
Compounds (PDCs) that have an affinity to certain tissue types and when light
activated have the ability to destroy the target cell. There are thousands of
potential applications of this technology including the destruction of: cancer,
bacteria and viruses. Theralase has a worldwide exclusive patent to a platform
of PDCs that are unique in that they are activated via a Type 1 reaction that
is independent of oxygen, an important characteristic, as solid core tumors
(i.e. breast, bladder, lung, brain, prostate, et cetera) are hypoxic (low
oxygen) in nature.
Products
1) TLC‐1000
Biomedical Laser Platform (to be phased out by 2014)
The TLC‐1000 therapeutic laser technology is a non‐invasive,
superpulsed, dual wavelength, multiple diode laser system that has three
specifically designed probes; a multiple probe used for neural muscular
skeletal conditions, a dermatological probe used for facial and small area
treatments and an acupuncture probe used for stimulation of acupuncture and
trigger points. The TLC‐1000 is FDA, Health Canada and CE approved and is the
current lead product in the Company’s US sales and marketing expansion. In
addition, Theralase has product distributors in the Middle East and China.
Theralase provides turnkey support on its technology,
enabling customers to deliver safe, effective and profitable rehabilitation
treatments including customer service, clinical training, new applications,
marketing and patient referrals.
2) TLC‐2000
Biofeedback Laser Platform (Launch date: 4Q2013)
The Theralase TLC‐2000 biofeedback laser system is a quantum
leap forward in therapeutic laser technology. The TLC-2000 is able to measure a
patient’s optical profile in a matter of seconds and then deliver a precise,
clinical dosage of energy to their specific condition in a matter of minutes.
Clinically effective dosages specific to optical tissue profiles will be stored
in a HIPAA compliant central databank and be available real time to all
practitioners utilizing the TLC‐2000 therapeutic laser. The TLC‐2000 laser
system is also a learning device that remembers the most clinically effective
treatments performed by practitioners and transmits this information to the
central databank for the benefit of all users. Theralase is currently
commercializing the technology and plans to introduce the TLC‐2000 laser system
to the international medical market in 4Q2013. Theralase in keeping with its
mandate of world-class customer service will allow every Theralase customer,
the ability to trade up to the new state of the art TLC‐2000 laser system. In
order to allow all laser practitioners a common tool to use in the delivery of
precision therapeutic laser treatments, Theralase will allow purchasers of
competitive products the ability to trade up to the TLC‐2000, under certain
terms and conditions.
The TLC‐2000 will also be used to launch Theralase into a
new business model, the recurring revenue model; whereby:
Theralase will provide the technology, training, ongoing service
and ongoing marketing / customer referrals for a one time up-front fee, plus a small
portion of each treatment delivered. In this model, Theralase will partner with
medical practitioners by lowering the up-front cost of the equipment and
participating in each treatment delivered by the practitioner. The equipment
will be billed through the internet; thus, allowing real time payments and
control over non-payment by practitioners.
The Theralase TLC‐2000 biofeedback laser technology is
patented in the United States, five European countries and Canada.
Theralase therapeutic laser systems are manufactured in an
ISO‐13485 internationally certified medical manufacturing facility based in
Toronto, Ontario, Canada.
3) TLC‐3000
Photodynamic Compound (PDC) / Laser Technology Platform
This technology involves the research and development of Photodynamic
Compounds combined and activated by proprietary biomedical lasers for the
selective destruction of cancers, bacteria and viruses. The clinical
applications of this technology may possibly have a significant impact on one
of the most devastating diseases of our time.
Theralase has successfully completed Milestone 1 – in‐vitro Analysis in the R&D of this
technology and has successfully destroyed brain, breast and colon cancer cell
lines in an in‐vitro analysis in 2010.
Theralase has successfully completed Milestone 2 – Small Animal
in‐vivo preclinical analysis of the
PDC technology, which commenced in 2011 and was successfully completed in 2012.In
this phase, complete destruction of colon cancer in an orthotopic mouse model
was achieved with the mice now living cancer free for over 1 year post
treatment.
Theralase is currently pursuing Milestone 3a – Destruction
of bladder cancer in an orthotopic animal model.
Therapeutic Market
Therapeutic laser technology could potentially be used by
over 1 million healthcare practitioners and 300 million public consumers in the
US and Canada in the next 5 years.
The therapeutic laser market is extremely fragmented with no
one company seen as the industry leader. All companies claim to have the best
product in terms of efficacy, often without any scientific research support.
Theralase therapeutic lasers have been tested in gold standard blinded, randomised,
controlled clinical studies and have proven unequivocally that the Theralase
therapeutic laser system is clinically and statistically effective in reducing
pain and inflammation in a wide variety of patients. Many of Theralase’s clinical
studies have been peer-reviewed and accepted for publication in medical
journals as well as presented at international scientific conferences.
Strategic Opportunity
Theralase plans to introduce a new business mode in
therapeutic lasers, the recurring revenue model; whereby, Theralase will
provide the technology, training, service and customer referrals, in exchange
for an upfront fee and monthly usage fee. In this model, Theralase will partner
with the medical practitioner by lowering the up-front cost of the equipment
and participating in each treatment delivered by the practitioner. The
equipment will be billed through the internet; thus allowing real time payments
and control over non-payment by practitioners. Theralase expects to generate
annual recurring revenue of $48 to $60 million per year within the next 5 years
with 8,000 to 10,000 units in operation producing a minimum monthly revenue
stream of $500 per month per laser. This financial model has been successfully
employed by many Fortune 500 companies, including: cell phone, photocopier,
satellite and cable TV industries.
Cancer Market
Bladder cancer has been chosen as Theralase’s principal
cancer target for its lead PDC compound. Theralase PDCs have proved to be toxic
to bladder cancer cells when light activated (100% kill rate) at very low
effective concentrations.
$3.98 billion is spent annually for Bladder Cancer Treatment
in the USA. There are 73,000 new cases and over 15,000 deaths in the US each
year; worldwide 386,000 new bladder cancer cases occur annually.
Bladder cancer is the most expensive cancer to treat with a
recurrence rate of up to 80%. Standard treatment has remained relatively unchanged
with no new drugs approved since 1998.
Strategic Opportunity
Completion of a FDA Phase 1/2a clinical study in bladder
cancer within 3 years. Theralase would then move to sell all rights to the
bladder cancer PDC technology to a pharmaceutical company for a milestone
payment of between $113 to $362 million, research and development costs and would
include an annual royalty stream of $50 to 60 million for 17 years.
Sales
To roll-out the TLC‐2000 Biofeedback Laser Platform, Theralase
will implement a US and Canadian sales strategy which focuses on establishing
beach heads through physical locations in each of the 5 largest US states and 2
largest Canadian provinces by population; California, New York, Illinois,
Texas, Florida, Alberta and Ontario. A
1500 to 2000 square foot leased property will be secured in each of the major
cities of these territories and employ a full time receptionist, clinic manager,
multidisciplinary practitioners (revenue sharing basis) and a Territory Sales
Manager (TSM). The clinic manager will be responsible for clinic sales, while
the TSM will be responsible for product sales. The property will provide
multiple functions in one location; including: a multidisciplinary clinic used to
generate brand awareness and clinic sales to offset the overhead of the
facility, provide a training and teaching location for new practitioners,
provide a service depot for product warranty exchanges and provide a sales
location for the TSM to generate product sales and build a distribution network
of sales professionals to sell the Company’s products on a commission basis.
These 7 TSM’s will be supported by the Company with:
1) Affiliation with well-known teaching hospitals,
chiropractic, physical therapist and medical doctor teaching universities and colleges
to provide high-level clinical and testimonial support
3) Regional and national sales and marketing programs
focused on bringing healthcare practitioners to the clinic to learn about the
technology and become a “Theralase Certified Laser Center” in their area
4) National and regional marketing to patients about the
benefits of therapeutic laser technology including a presence at major
healthcare and industry conferences
5) Seminar and Webinar series to present Theralase’s technology
to healthcare practitioners
Key Employees and
Advisors
Roger Dumoulin-White, P.Eng,
President and CEO
Mr. Dumoulin-White founded Theralase in 1995 and has over 25 years as a
senior manager with private and public companies. As an award-winning
entrepreneur, he has pioneered Low-Level Laser Therapy for use in treating
pain, inflammation and for tissue regeneration of neural muscular skeletal
conditions and wound healing. He is responsible for developing patented Photo
Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria
and viruses when light activated by Theralase’s proprietary laser technology.
Kristina Hachey, CGA, CFO
Ms. Hachey has over 16 years of experience in finance and financings in
public and private companies.
Arkady Mandel, MD, Ph.D., D.Sc.,
Chief Scientific Officer
Dr. Mandel has over 20 years of experience as a key founder of
therapeutic uses of lasers in dermatology and other areas of clinical medicine.
He is an experienced executive manager of research and development teams
dedicated to the field of biotechnology, drug development and photobiology. He
has published over 100 original scientific papers to his name, combined with
over 200 international patents attributed to his research. He is an editor of many
peer reviewed scientific and medical journals.
Lothar Lilge, Ph.D., Professor
in the Department of Medical Biophysics, University of Toronto, Senior
Scientist at the Ontario Cancer Institute / Princess Margaret Cancer Centre / University
Health Network
Dr. Lilge's research is focused on photodynamic therapy (PDT), optical
diagnostics, destruction of cancer and bacteria by light activated PDTs and the
use of light as a microscopic tool for biomedical research. He has published over
30 original scientific papers and is an editor of peer reviewed scientific
journals. Dr. Lilge is a much sought after speaker at many international
medical and scientific conferences.
Michael Jewett, MD, FRCSC, FACS,
Professor of Surgery in the Division of Urology at the University of Toronto, a
member of the Department of Surgical Oncology at Princess Margaret Cancer
Centre and of the Division of Urology at the University Health Network. He is a
member of Theralase’s Medical and Scientific Advisory Board. Dr. Jewett is
internationally known for his contributions in the fields of bladder, testis
and kidney cancer fundamental and clinical research. He has been the Principal
Investigator/Co-Principal Investigator on over 60 Phase I-Phase III clinical
trials and the Lead Principal Investigator of several Cooperative Group Trials.
These clinical trials have primarily been focused on proving the safety,
efficacy and clinical benefits of technology in the destruction of cancer, with
the ultimate goal of achieving FDA or Health Canada clinical approval. He is a
recent Past-President of the Canadian Urology Association and a member of many
urological and surgical oncology societies worldwide. Dr. Jewett has published
over 175 original medical research papers.
James Andrews, MD, Founding
member of Andrews Sports Medicine and Orthopaedic Center in Birmingham,
Alabama. He is also a founder of the American Sports Medicine Institute (ASMI)
a non-profit institute dedicated to injury prevention, education and research
in orthopaedics and sports medicine. He is a member of Theralase’s Medical and
Scientific Advisory Board. Doctor Andrews is internationally known and
recognized for his skills as an orthopaedic surgeon as well as his scientific
and clinic research contributions in knee, shoulder and elbow injury prevention
and treatment. Doctor Andrews is Senior Consultant for the Washington Redskins
Professional Football team and Medical Director for the Tampa Bay Rays
Professional Baseball Team and the Ladies Professional Golf Association.
For further information, please call 1-866-843-5273 or visit www.theralase.com
Thursday, May 2, 2013
Theralase Announces 2012 Year End Financials
Theralase Advances Therapeutic Laser and Cancer Destruction
Technologies
Toronto, Ontario – May 1, 2013, Theralase Technologies Inc. (TSXV: TLT)
announced its year end 2012 financial results today.
Total revenue for the twelve month period ended December
31, 2012 dipped slightly to $1,824,313 compared to $2,027,058 for the same
period in 2011, a 10% reduction, primarily due to a reduction in laser sales in
the US and internationally. In 2012, Theralase focused its efforts on laser
sales in Canada for its Therapeutic Laser Technology (TLT) Division and for
accelerating the research and development of its patented cancer destruction
platform for its Photo Dynamic Therapy (PDT) Division.
Selling expenses decreased by 41%, to $626,380 for
the twelve month period ended December 31, 2012 compared to $1,060,288 for the
same period in 2011. The percentage decrease was due to decreased spending on salaries,
marketing, advertising and travel related expenses, as more focus was paid to
completing sales in Canada, than abroad.
Administrative expenses increased from $1,028,431
for the twelve months ended December 31, 2011 to $1,238,900 for the same period
in 2012 representing an increase of 20%. The increase in administrative
expenditures was primarily due to increases in the costs associated with stock based
compensation.
Research and development
costs increased to $873,335 for the year ended December 31, 2012
compared to $759,352 for the previous year, representing a 15% increase, due in
part to the costs required to commercialize the TLC-2000 biofeedback laser, but
primarily due to research and development costs of the TLC-3000 Photo Dynamic
Compound (PDC) cancer and bacteria destruction technology.
The net loss for
the year ended December 31, 2012 was $1,509,569, which included $322,915 of net
non-cash expenses (amortization, stock-based compensation expense, foreign
exchange gain/loss, equipment write-off and lease inducements) compared to a
net loss in 2011 of $1,453,974, which included $74,921 of net non-cash expenses. The
increase in net loss is due to increases
in the costs associated with stock based compensation, commercialization
of the patented TLC-2000 Biofeedback
Therapeutic Laser due for launch in 2013 and primarily due to the research and
development of the TLC-3000 Photo Dynamic Compound cancer destruction
technology due for completion of the pre-clinical phase by 4Q2013.
Theralase has had
many successes in 2012, specifically:
- Preclinical research that confirmed the complete
destruction of subcutaneous (under the skin) colon cancer tumours in mouse
subjects, which were treated with the Theralase anti-cancer Photo Dynamic
Compound (PDC) technology, which have continued to thrive cancer-free for
more than 1 year post-treatment without any side effects.
- Bladder cancer named as the principal cancer
target
- Theralase’s PDC was found to be 100% effective
in destroying bladder cancer tumour cells
- Theralase PDCs have shown an ability to destroy
Escherichia Coli (E. coli) and Listeria Monocytogenes (Listeria) bacteria in vitro when light activated
- Theralase establishes laser distributors in the
Middle East and China
- Addition of TENS (Transcutaneous Electrical
Nerve Stimulation) on select laser models to allow additional CPT billing
codes for the US market
- Theralase's innovative anti-cancer PDC technology
validated at major international conferences
- Theralase expands intellectual property portfolio
with increased patent protection
- Renowned oncologist Dr. Michael Jewett joins Theralase's
medical and scientific advisory board
Roger Dumoulin-White, President and CEO of
Theralase Technologies Inc. stated, “The Company has completed the research and
development of its next generation, patented TLC-2000 Biofeedback Therapeutic
Laser and is now preparing for its launch in 4Q2013. In addition, Theralase has
made great strides forward in the research and development of its patented
Photo Dynamic Compounds (PDCs), indicated for the destruction of specific cancerous
tumours. Our first target, bladder cancer, should be ready for human trials as
early as 2014. In order to capitalize on this state-of-the-art cancer
destruction technology and dramatically increase shareholder value, Theralase
is in negotiations with strategic partners focused on the early
commercialization of this ground breaking technology.”
About Theralase Technologies Inc.
Theralase Technologies Inc., founded in 1995,
designs, develops, manufactures and markets patented, superpulsed laser
technology utilized in biostimulation and biodestruction applications.
Theralase technology is safe and effective in treating pain, inflammation and
for tissue regeneration of neural muscular skeletal conditions and wound
healing. As well, these applications extend to the care of animals by
veterinarians. Theralase is currently developing patented Photo Dynamic
Compounds (PDCs) that are able to target and destroy cancers, bacteria and
viruses when light activated by Theralase’s proprietary laser technology.
The complete consolidated financial statements
and MD&A for twelve months ending December 31, 2012 may be viewed at www.theralase.com and www.sedar.com
.
This press release contains forward-looking statements, which reflect
the Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ
materially from those projected herein. The Company disclaims any obligation to
update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchanges) accepts
responsibility for the adequacy or accuracy of this release.
For More Information, please contact:
Roger Dumoulin-White,
President & CEO
416-699-LASE (5273) ext. 225
Kristina Hachey
Chief Financial Officer
416-699-LASE (5273) ext. 224
Greg Bewsh
Director of Investor Relations
416-699-LASE (5273) ext. 258
Arkady
Mandel
Chief
Scientific Officer
416-699-LASE (5273) ext.
260
Friday, April 26, 2013
COLD LASER THERAPY BASICS
Over 75 Trillion cells in a human body and they all need energy and electrons to communicate with each other. Laser light delivers the required electrons and energy directly to the cells, enhancing their ability to communicate with each other, absorb oxygen and nutrients and dispose of wastes and toxins. The laser delivers photons to the cells, and mitochondria, which they convert into ATP and use as energy for rebuilding and repairing tissues, tendons, ligaments, nerves and even bones.
Laser therapy is an exciting and relatively new field that can offer people a very safe and effective option to help with speeding up injury repair and reducing pain. provides a unique alternative to patients who are terrified of surgery or drugs, but still seek the powerful healing benefits.
A laser is defined as a device that produces intense radiation in the visible or near visible wavelengths. Laser light is unique in that it is close to one specific wavelength and propagates in-phase; meaning that all of the electro-magnetic waves oscillate together in an ordered and aligned way. Together, these conditions make up the term coherency. When the coherent light is columnated, it can travel vast distances with very little loss of power or scattering
Laser treatment used for healing is called “low-level laser” or “cold-laser” therapy. By definition, lasers used for cold-laser therapy range in power from 5 to 500 milliwatts (0.005 to 0.5 Watts). Lasers less than 5 milliwatts lack the power to induce a bio-stimulatory effect, while lasers greater than 500 milliwatts may cause excessive heating and burn the skin. Lasers used for surgery, however, range from 5 to 50 Watts
Approximately 3,000 clinical studies worldwide have attested to the beneficial and curative effects of therapeutic lasers.
Cold-laser therapy systems are available in several different wavelengths and colors…
A lot depends on what you are trying to heal. Each color reacts differently with the body.
Red lasers (660 nm) can penetrate more deeply, but are still generally used for surface conditions such as healing surface wounds such as bed-sores or diabetic ulcers,burns, acne, and hair restoration.
infrared lasers (905 nm) penetrate much deeper and are used to help heal muscle, ligament, and even bone.
The health benefits of cold laser therapy can be roughly divided into three categories:
1) Reduce inflammation
2) Reduce pain
3) Accelerate tissue repair
Laser Acupuncture
An increasing body of evidence suggests that laser treatments on specific acupuncture points can stimulate a similar effect as acupuncture needles.The use of laser acupuncture in the ears to help addiction and weight management cases
Dangers & Risks
One of the greatest risks of laser therapy is damage to the eyes. Cold-laser therapy treatments should always be conducted with proper safety glasses worn by both the patient and the practitioner. Other contraindications for laser treatment include:
• No treatment over suspect tumors or cancer cells
• No treatment over the thyroid
• No treatment over the fontanelle of infants
• No treatment if the patient is using photo-sensitive or immunosuppressant drugs.
These potential risks are a conservative precaution. Special exceptions are already being discovered including the use of laser-therapy to help with macular degeneration
Checklist to laser therapy
Adherence to the laser dosage recommendations from the world association for laser therapy is very important: the eight most important beam parameters are: wavelength, power, irradiation time, beam area at the skin or culture surface , pulse parameters, anatomical location, number of treatments, and interval between treatments.
The three commonly used dose parameters are time, energy, and energy density.
In addition coherence, application technique(contact, projection, scanning, pressure), beam profile, and spectral width may also be considered important.
Beam power often decreases as the device warms up and as the device ages
For further information please call 1-866-843-5273 or visit www.theralase.com
Friday, April 19, 2013
Theralase’s Innovative Anti-Cancer Technology Validated at Major International Conferences
Toronto, Ontario – April 19, 2013 -- Theralase Technologies Inc.
(TSX-V: TLT) announced today that its innovative Photo Dynamic Compound (PDC) technology
has been accepted for presentation at two major international scientific
conferences. Acceptance at these conferences validates the significance of the technology
and its efficacy in the destruction of cancer cells in research performed by
Theralase's internationally acclaimed scientists.
The efficacy of the anti-cancer Photo Dynamic Compound technology will
be presented at LASER World of Photonics conference in Munich, Germany on May
15, 2013.
The effective destruction of bacteria using Theralase’s light activated
Photo Dynamic Compound technology will be presented at
Photonics North conference in Ottawa, Canada on June 3, 2013.
In further developments, Theralase’s Chief Scientific Officer, Dr.
Arkady Mandel has been elected to the Editorial Board of Photonics & Lasers
in Medicine (PLM) journal and chosen as issue editor of PLM for the Low Level
Laser Therapy (LLLT) issue. PLM is an internationally peer-reviewed journal,
which publishes clinical and scientific studies concerned with the clinical and
scientific application of lasers and biophotonics in medicine for diagnostic
and therapeutic purposes. PLM recently featured the clinical success of Theralase’s
pivotal randomized placebo controlled clinical trial entitled, “Laser Therapy
Applications for Osteoarthritis and Chronic Joint Pain.”
Roger Dumoulin-White, President and CEO of Theralase said, "I am
pleased that Theralase’s scientific and clinical research has been recognized
and acclaimed by two of the finest international scientific conferences and has
been published in a peer reviewed medical journal. Theralase is committed to
the early commercialization of its patented light activated Photo Dynamic
Compounds in the areas of anti-cancer and anti-bacterial applications to generate
substantial revenue increases for the Company. To accelerate this process, we
are actively looking to collaborate with strategic partners to further develop
our
technologies and increase shareholder value. Theralase’s strong PDC pipeline has
scientifically proven that our PDC technology is capable of consistently
producing cell kill levels of 100%, even at very low concentrations, across a
wide range of cancers and bacteria. In fact, our PDCs have been proven to be significantly
more effective in destroying cancer cells and bacteria than currently FDA
approved Photo Dynamic Compounds.”
About
Theralase Technologies Inc.:
Theralase Technologies Inc., founded in 1995, designs, develops,
manufactures and markets patented, superpulsed laser technology utilized in
biostimulation and biodestruction applications. Theralase technology is safe
and effective in treating pain, inflammation and for tissue regeneration of
neural muscular skeletal conditions and wound healing. Theralase is currently
developing patented Photo Dynamic Compounds (PDCs) that are able to target and
destroy cancers, bacteria and viruses when light activated by Theralase’s proprietary
laser technology.
For further information please
visit www.theralase.com , regulatory
filings may be viewed by visiting www.sedar.com.
This press release contains forward-looking statements, which reflect
the Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ
materially from those projected herein. The Company disclaims any obligation to
update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchanges) accepts
responsibility for the adequacy or accuracy of this release.
For More Information
Roger Dumoulin-White
President & CEO
416-699-LASE (5273) ext. 225
rwhite@theralase.com
Kristina Hachey
Chief Financial Officer
416-699-LASE (5273) ext. 224
khachey@theralase.com
Arkady Mandel
Chief Scientific Officer
416-699-LASE (5273) ext. 260
amandel@theralase.com
Greg Bewsh
Director of Investor Relations
416-699-LASE (5273) ext. 258
gbewsh@theralase.com
Friday, April 12, 2013
TSX Venture Exchange Has Consented to the Extension of Warrants
THERALASE TECHNOLOGIES INC. ("TLT")
BULLETIN TYPE: Warrant Term Extension
BULLETIN DATE: April 11, 2013
TSX Venture Tier 2 Company
BULLETIN TYPE: Warrant Term Extension
BULLETIN DATE: April 11, 2013
TSX Venture Tier 2 Company
TSX Venture Exchange has consented to the extension in the expiry date of the following warrants:
Private Placement:
| # of Warrants: Original Expiry Date of Warrants: New Expiry Date of Warrants: Exercise Price of Warrants: | 1,500,000 April 13, 2013 April 13, 2017 $0.38 | ||||||||||
These warrants were issued pursuant to a private placement of 3,000,000 shares with 1,500,000 share purchase warrants attached, which was accepted for filing by the Exchange effective April 16, 2012.
For further information please call 1-866-843-5273 or visit www.theralase.com
Monday, April 1, 2013
Theralase Applies to TSX Venture Exchange for Warrant Extension
Toronto, ON – March 28, 2013 - Theralase
Technologies Inc. (TSXV: TLT) (“Theralase”) announced today that it has made
application to the TSX Venture Exchange for approval to extend the expiry date
of its outstanding common share purchase warrants.
Theralase has applied to have the expiry date of
the warrants amended from April 13, 2013 to April 13, 2017 for the 1,500,000 total
warrants issued on April 13, 2012. The exercise price of the warrants remains
unchanged at $0.38 per warrant, with the exception that the warrants will be
cancelled if they are not exercised within thirty (30) days from written notice
that the closing price of Theralase’s common
shares had been $0.75 or greater for 10 consecutive trading days.
About
Theralase Technologies Inc.:
Theralase Technologies Inc., founded in 1995, designs, develops,
manufactures and markets patented, superpulsed laser technology utilized in
biostimulation and biodestruction applications. Theralase technology is safe
and effective in treating pain, inflammation and for tissue regeneration of
neural muscular skeletal conditions and wound healing. Theralase is currently
developing proprietary Photo Dynamic Compounds (PDCs) that are able to target
and destroy cancers, bacteria and viruses when light activated by Theralase’s
proprietary and patented laser technology.
For further information please visit www.theralase.com
, regulatory filings may be viewed by visiting www.sedar.com.
This press release contains forward-looking statements, which reflect
the Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ
materially from those projected herein. The Company disclaims any obligation to
update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchanges) accepts
responsibility for the adequacy or accuracy of this release.
For More Information:
Roger Dumoulin-White
President & CEO
416-699-5273 ext. 225
Kristina Hachey
Chief Financial Officer
416-699-5273 ext. 224
Greg Bewsh
Director of Investor Relations
416-699-5273 ext. 258
Friday, March 22, 2013
Why Invest in Theralase?
For more information, please call 1-866-843-5273 or visit www.theralase.com
Thursday, March 14, 2013
Theralase Achieves Commercialization Milestone For Its Bladder Cancer Therapy
Toronto, ON -- March 14, 2013 -- Theralase
Technologies Inc. (TSXV: TLT) announced that its proprietary Photo Dynamic
Compound (PDC) technology has been approved for use in a live animal bladder
cancer model by the University Health Network (UHN) Research Ethics Board. This
approval expedites the Company’s progress towards commercializing its advanced
bladder cancer therapy.
Theralase’s leading proprietary oncology PDC has
repeatedly demonstrated that it is:
- toxic to bladder
cancer cells when light activated (100% kill rate)
- exceeds potency
of FDA approved PDCs
- highly stable
ensuring optimal tumour destruction
Theralase will validate its PDC technology in this animal
cancer model to support an Investigational New Drug (IND) application to be
filed with the FDA later this year. This IND application will allow Theralase
to commence a Phase 1/2a human clinical trial to prove the safety and efficacy
of its PDC technology on a 30 subject population with scheduled completion in
2014. Based on recent pharmaceutical acquisitions for oncology drugs and market
statistics, the estimated value of the PDC upon successful completion of a FDA
Phase 1/2a clinical trial ranges from $84 million to $360 million in upfront
payments followed by a double digit revenue royalty stream. (Source: BIO
statistics)
Arkady Mandel MD, PhD, DSc, Chief Scientific
Officer of Theralase Technologies Inc. stated, “Protocols and standard operating
procedures are in place to ensure adherence to the highest scientific and
ethical standards. In addition, the program has been fully accredited by the
Canadian Council for Animal Care. This critical research is a vital progressive
step that will greatly advance our innovative bladder cancer therapy.”
Michael Jewett, FRCSC, MD, an eminent urologist and
a member of the Department of Surgical
Oncology at UHN’s Princess Margaret Cancer Centre, as well as a member of
Theralase’s Medical and Scientific Advisory Board said, “The elements of
Theralase’s PDC development plan are in place and I believe they will lead to a
successful FDA Phase 1/2a human clinical bladder cancer trial to commence early
next year. With a recurrence rate of nearly 80%, bladder cancer is the most
expensive cancer to treat on a per patient basis and raises many issues
affecting the quality of life because of its persistence.”
Roger Dumoulin-White, President and CEO of
Theralase Inc. stated, “Our leading PDC drug candidate has been proven to be
superior to any currently approved FDA PDC on the market. As we continue to achieve
our critical research milestones, Theralase’s leading PDC provides indisputable
proof of its efficacy in the destruction of cancer in live animal models.
Subject to a successful FDA Phase 1/2a human clinical bladder cancer trial of
the PDC technology, Theralase will apply for “breakthrough status” with the FDA,
which if granted, would allow Theralase the unique opportunity of
commercializing its technology without the need for further FDA clinical
trials, thus allowing the bladder cancer technology the most direct route to fulfill
an unmet medical need and aid in the destruction of a deadly disease.”
About
Theralase Technologies Inc.:
Theralase Technologies Inc., founded in 1995, designs, develops,
manufactures and markets patented, superpulsed laser technology utilized in
biostimulation and biodestruction applications. Theralase technology is safe
and effective in treating pain, inflammation and for tissue regeneration of
neural muscular skeletal conditions and wound healing. Theralase is currently
developing patented Photo Dynamic Compounds (PDCs) that are able to target and
destroy cancers, bacteria and viruses when light activated by Theralase’s
proprietary and patented laser technology.
For further information please
visit www.theralase.com , regulatory
filings may be viewed by visiting www.sedar.com.
This press release contains forward-looking statements, which reflect
the Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ
materially from those projected herein. The Company disclaims any obligation to
update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchanges) accepts
responsibility for the adequacy or accuracy of this release.
For More Information:
Roger Dumoulin-White
President & CEO
416-699-5273 ext. 225
rwhite@theralase.com
Subscribe to:
Posts (Atom)